Literature DB >> 22903236

Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant.

Minoru Tada1, Akiko Ishii-Watabe, Keiko Maekawa, Hiromi Fukushima-Uesaka, Kouichi Kurose, Takuo Suzuki, Nahoko Kaniwa, Jun-Ichi Sawada, Nana Kawasaki, Takako Eguchi Nakajima, Ken Kato, Yasuhide Yamada, Yasuhiro Shimada, Teruhiko Yoshida, Takashi Ura, Miyuki Saito, Kei Muro, Toshihiko Doi, Nozomu Fuse, Takayuki Yoshino, Atsushi Ohtsu, Nagahiro Saijo, Haruhiro Okuda, Tetsuya Hamaguchi, Yoshiro Saito, Yasuhiro Matsumura.   

Abstract

Fcγ receptor IIa (FcγRIIa) plays an important role in antibody-dependent cellular cytotoxicity and inflammation. Changes in FcγRIIa expression levels or activity caused by genetic polymorphisms in FCGR2A, the gene encoding FcγRIIa, may lead to differences in disease progression as well as efficacy of antibody therapeutics between individuals. In this study, we sequenced the 5'-flanking region along with all exons and their flanking regions of FCGR2A from 111 Japanese subjects. Forty-eight genetic variations were found including 12 novel ones. Beside the well-known functional 497A > G (H166R) polymorphism, we detected 818T > C (L273P) at 0.005 frequency. Since the functional significance of this polymorphism has not been revealed, we next assessed the functions of the L273P substitution by expressing wild-type and the variant proteins in human Jurkat cells. The L273P variant protein showed similar cell surface expression and IgG-binding properties as the wild-type, but it exhibited a stronger signal transduction activity based on the approximately 2-fold enhancement of tyrosine phosphorylation of FcγRIIa itself. The current results suggest that L273P could have functional significance in the antibody-dependent clinical responses through FcγRIIa.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22903236     DOI: 10.1007/s00251-012-0646-9

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  18 in total

1.  Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease.

Authors:  Chiea Chuen Khor; Sonia Davila; Willemijn B Breunis; Yi-Ching Lee; Chisato Shimizu; Victoria J Wright; Rae S M Yeung; Dennis E K Tan; Kar Seng Sim; Jie Jin Wang; Tien Yin Wong; Junxiong Pang; Paul Mitchell; Rolando Cimaz; Nagib Dahdah; Yiu-Fai Cheung; Guo-Ying Huang; Wanling Yang; In-Sook Park; Jong-Keuk Lee; Jer-Yuarn Wu; Michael Levin; Jane C Burns; David Burgner; Taco W Kuijpers; Martin L Hibberd
Journal:  Nat Genet       Date:  2011-11-13       Impact factor: 38.330

2.  The rs150311303 polymorphism in FcγRIIa enhances IgG binding capacity.

Authors:  A H Omar; H Shibata; M Yasunami; A Yamazaki; M F Ofori; B D Akanmori; M N Shuaibu; M Kikuchi; K Hirayama
Journal:  Scand J Immunol       Date:  2012-08       Impact factor: 3.487

3.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

Authors:  Pierre Bruhns; Bruno Iannascoli; Patrick England; David A Mancardi; Nadine Fernandez; Sylvie Jorieux; Marc Daëron
Journal:  Blood       Date:  2008-11-18       Impact factor: 22.113

4.  Fc receptor-mediated platelet activation is dependent on phosphatidylinositol 3-kinase activation and involves p120(Cbl).

Authors:  A Saci; S Pain; F Rendu; C Bachelot-Loza
Journal:  J Biol Chem       Date:  1999-01-22       Impact factor: 5.157

5.  FcgammaRIIA exogenously expressed in HeLa cells activates the mitogen-activated protein kinase cascade by a mechanism dependent on the endogenous expression of the protein tyrosine kinase Syk.

Authors:  M A Renedo; N Fernández; M S Crespo
Journal:  Eur J Immunol       Date:  2001-05       Impact factor: 5.532

Review 6.  Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.

Authors:  P Mark Hogarth; Geoffrey A Pietersz
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

7.  Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.

Authors:  Tanja Schneider-Merck; Jeroen J Lammerts van Bueren; Sven Berger; Kai Rossen; Patrick H C van Berkel; Stefanie Derer; Thomas Beyer; Stefan Lohse; Wim K Bleeker; Matthias Peipp; Paul W H I Parren; Jan G J van de Winkel; Thomas Valerius; Michael Dechant
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

Review 8.  The role of FcgammaRIIa as an inflammatory mediator in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Caroline Tan Sardjono; Patricia L Mottram; P Mark Hogarth
Journal:  Immunol Cell Biol       Date:  2003-10       Impact factor: 5.126

9.  Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans.

Authors:  J E Salmon; S Millard; L A Schachter; F C Arnett; E M Ginzler; M F Gourley; R Ramsey-Goldman; M G Peterson; R P Kimberly
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

10.  Phosphorylation of FcgammaRIIA is required for the receptor-induced actin rearrangement and capping: the role of membrane rafts.

Authors:  Katarzyna Kwiatkowska; Jürgen Frey; Andrzej Sobota
Journal:  J Cell Sci       Date:  2003-02-01       Impact factor: 5.285

View more
  2 in total

1.  Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies.

Authors:  Minoru Tada; Akiko Ishii-Watabe; Takuo Suzuki; Nana Kawasaki
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

Review 2.  Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine.

Authors:  Sietse Q Nagelkerke; David E Schmidt; Masja de Haas; Taco W Kuijpers
Journal:  Front Immunol       Date:  2019-10-03       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.